AbbVie Inc. (ABBV)

NYSE: ABBV · IEX Real-Time Price · USD
+2.07 (1.26%)
At close: May 17, 2024, 4:00 PM
-0.04 (-0.02%)
After-hours: May 17, 2024, 7:59 PM EDT
Market Cap 293.68B
Revenue (ttm) 54.40B
Net Income (ttm) 5.99B
Shares Out 1.77B
EPS (ttm) 3.37
PE Ratio 49.38
Forward PE 13.77
Dividend $6.20 (3.73%)
Ex-Dividend Date Apr 12, 2024
Volume 2,961,276
Open 165.39
Previous Close 164.35
Day's Range 164.49 - 166.49
52-Week Range 130.96 - 182.89
Beta 0.59
Analysts Buy
Price Target 180.55 (+8.49%)
Earnings Date Apr 26, 2024

About ABBV

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; E... [Read more]

Sector Healthcare
CEO Richard A. Gonzalez
Employees 50,000
Stock Exchange NYSE
Ticker Symbol ABBV
Full Company Profile

Financial Performance

In 2023, AbbVie's revenue was $54.32 billion, a decrease of -6.44% compared to the previous year's $58.05 billion. Earnings were $4.86 billion, a decrease of -58.91%.

Financial Statements

Analyst Forecast

According to 12 analysts, the average rating for ABBV stock is "Buy." The 12-month stock price forecast is $180.55, which is an increase of 8.49% from the latest price.

Price Target
(8.49% upside)
Analyst Consensus: Buy
Stock Forecasts


AbbVie Presents New Data Supporting Leading Gastroenterology Portfolio at 2024 Digestive Disease Week®

-    AbbVie will present 15 abstracts, including three oral presentations, in Crohn's disease and ulcerative colitis reinforcing AbbVie's commitment to advancing the standards of care in inflammatory ...

1 day ago - PRNewsWire

Alzamend Neuro Announces Initial Closing of Private Placement

ATLANTA--(BUSINESS WIRE)---- $ABBV #15_Percent_Interest_Bearing_Preferred_Stock--Alzamend Neuro Announces Initial Closing of Private Placement; Investor Purchase Up to $25 Million of Preferred Shares;...

4 days ago - Business Wire

AbbVie and Gilgamesh Pharmaceuticals Announce Collaboration and Option-to-License Agreement to Develop Next-Generation Therapies for Psychiatric Disorders

-   Collaboration to leverage AbbVie's psychiatry expertise and Gilgamesh's innovative research platform to develop next-generation neuroplastogens for the treatment of psychiatric disorders NORTH CHI...

5 days ago - PRNewsWire

LANDOS BIOPHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Landos Biopharma, Inc. - LABP

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Landos Biopharma...

Other symbols: LABP
7 days ago - Business Wire

Alzamend Neuro Announces Agreement for Registered Direct Offering and Concurrent Private Placement for an Aggregate of up to $25 Million

ATLANTA--(BUSINESS WIRE)---- $ABBV #15_Percent_Interest_Bearing_Preferred_Stock--Alzamend Neuro Announces Agreement for Registered Direct Offering and Concurrent Private Placement for an Aggregate of ...

9 days ago - Business Wire

AbbVie to Present at the Bank of America Securities Healthcare Conference

NORTH CHICAGO, Ill. , May 6, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Bank of America Securities Healthcare Conference on Wednesday, May 15, 2024.

12 days ago - PRNewsWire

Healthy Returns: Sales of Humira are plunging, but AbbVie has two promising successors

AbbVie has two successors that could offset the losses from its blockbuster drug Humira. Meanwhile, UnitedHealth Group's CEO will testify on Capitol Hill.

17 days ago - CNBC

FTC challenges ‘bogus' patents on Ozempic, other drugs that ‘block competition'

WASHINGTON — Federal regulators are challenging patents on 20 brand-name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting indu...

Other symbols: AZNGSKNVO
18 days ago - Market Watch

AbbVie Stock Falls As Company Warns of Continued Humira Sales Slump

Shares of AbbVie (ABBV) slumped Friday as the pharmaceutical firm warned of deeper declines in sales of its blockbuster arthritis drug, Humira, because of competition from close copies known as biosim...

22 days ago - Investopedia

AbbVie's Q1 earnings beat expectations as arthritis drug boosts growth

Pharmaceuticals company AbbVie (NYSE: ABBV) reported its Q1 financial results for 2024 today. AbbVie's earnings came in at $1.37 billion, or $0.77 per share, as compared with $239 million, or $0.13 pe...

22 days ago - Invezz

AbbVie Raises Earnings Guidance Even as Humira Sales Continue to Fall

AbbVie reports better-than-expected adjusted earnings in the first quarter.

22 days ago - Barrons

AbbVie lifts profit forecast after Skyrizi sales beat expectations

AbbVie raised its annual profit forecast on Friday after strong sales of its immunology drug Skyrizi and cancer drug Imbruvica helped the company beat Wall Street estimates for the first quarter.

22 days ago - Reuters

AbbVie's first-quarter results top expectations as arthritis drugs fuel growth

AbbVie Inc. on Friday reported first-quarter results that beat expectations, even as sales of blockbuster autoimmune drug Humira continued to fall amid new, lower-cost competition.

22 days ago - Market Watch

AbbVie Reports First-Quarter 2024 Financial Results

Reports First-Quarter Diluted EPS of $0.77 on a GAAP Basis, an Increase of 492.3 Percent; Adjusted Diluted EPS of $2.31, a Decrease of 6.1 Percent; These Results Include an Unfavorable Impact of $0.08...

22 days ago - PRNewsWire

AbbVie's skin disease drug found to be more effective than Regeneron's Dupixent in study

AbbVie said on Thursday its drug, Rinvoq, for treating a type of inflammatory skin condition was found to be more effective than Regeneron Pharmaceuticals and Sanofi's Dupixent in a late-stage head-to...

23 days ago - Reuters

New Data Show RINVOQ® (upadacitinib) Demonstrated Superiority Versus DUPIXENT® (dupilumab) Across Primary and All Secondary Endpoints in an Open-Label Head-to-Head Atopic Dermatitis Study

Upadacitinib demonstrated superiority versus dupilumab in primary endpoint of simultaneous achievement of near complete skin clearance (EASI 90) and no to little itch (WP-NRS 0/1) at Week 161 LEVEL UP...

23 days ago - PRNewsWire

Allergan Aesthetics Invites Consumers to Be the Face of BOTOX® Cosmetic (onabotulinumtoxinA) and Their Other Biggest Brands

Consumers Can Apply for a Chance to Be Featured in Upcoming Campaigns for BOTOX® Cosmetic, the JUVÉDERM® Collection of Fillers, and Allē, the Allergan Aesthetics Loyalty Rewards Program IRVINE, Calif....

25 days ago - PRNewsWire

Phase 3 SELECT-GCA Study of Upadacitinib (RINVOQ®) Showed Positive Results in Patients With Giant Cell Arteritis

−     Results from the Phase 3 SELECT-GCA study showed 46 percent of patients with giant cell arteritis (GCA) who were treated with upadacitinib (RINVOQ®; 15 mg) with a 26-week steroid taper regimen a...

4 weeks ago - PRNewsWire

Medincell Enters Into Strategic Co-development and Licensing Agreement with AbbVie to Develop Next-generation Long-acting Injectable Therapies

MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: Medincell (Paris:MEDCL) today announced a collaboration with AbbVie to co-develop and commercialize up to six therapeutic products across multipl...

4 weeks ago - Business Wire

These four halal, Shariah-compliant stocks are best buys after Eid al-Fitr

If you want to invest in some new halal stocks, you know that finding companies compliant with Shariah law can be complicated.

Other symbols: ISRGSSNLFXOM
4 weeks ago - Invezz

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of AbbVie Inc. (ABBV) on Behalf of Investors

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of AbbVie Inc. (“Abb...

5 weeks ago - Business Wire

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of AbbVie Inc. (ABBV) on Behalf of Investors

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of AbbVie Inc. (“AbbVie” or the “Company”) (NYSE: ABBV) investors concerning the Company's possible ...

5 weeks ago - Business Wire

AbbVie Announces Late-Breaking Data at AAN Supporting Long-Term Safety and Efficacy of Atogepant (QULIPTA®) for Preventive Treatment of Migraine

-     Interim analysis of an ongoing 156-week extension study supports long-term safety, tolerability and efficacy of atogepant 60 mg to prevent chronic and episodic migraine -     Seventy percent of ...

5 weeks ago - PRNewsWire

The Law Offices of Frank R. Cruz Announces Investigation of AbbVie Inc. (ABBV) on Behalf of Investors

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of AbbVie Inc. (“AbbVie” or the “Company”) (NYSE: ABBV) on behalf of investors concerning the Company's possib...

5 weeks ago - Business Wire

SkinMedica® Empowers Clear Skin Confidence with a New, Modern Approach to Acne

From the makers of BOTOX ® Cosmetic, two new SkinMedica ®  acne products help address skin blemishes and can be combined with in-office DiamondGlow ® IRVINE, Calif. , April 9, 2024 /PRNewswire/ -- All...

5 weeks ago - PRNewsWire